SAVENE ® Manufacturer advises avoid (no information available).

- **RENAL IMPAIRMENT**

CARDIOXANE ® **DOSE ADJUSTMENTS** Manufacturer advises reduce dose by 50% if creatinine clearance less than 40 mL/minute.

SAVENE ® Manufacturer advises avoid—risk of accumulation.

- **MONITORING REQUIREMENTS**
  - Monitor full blood count.
  - Monitor for cardiac toxicity.
  - Monitor liver function.
- **DIRECTIONS FOR ADMINISTRATION** Local coolants such as ice packs should be removed at least 15 minutes before administration.

CARDIOXANE ® For *intravenous infusion*, give intermittently *in* Compound sodium lactate; reconstitute each vial with 25 mL water for injections and dilute each vial with 25–100 mL infusion fluid; give requisite dose over 15 minutes.

SAVENE ® For *intravenous infusion*, give intermittently *in* diluent; reconstitute each 500-mg vial with 25 mL of diluent; dilute requisite dose further in remaining diluent and give over 1–2 hours into a large vein in an area other than the one affected.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for infusion

- Cardioxane (Clinigen Healthcare Ltd)

Dexrazoxane 500 mg Cardioxane 500mg powder for solution for infusion vials | 1 vial PoM £156.57

Powder and solvent for solution for infusion

ELECTROLYTES: May contain Potassium, sodium

- Savene (Clinigen Healthcare Ltd)

Dexrazoxane 500 mg Savene 500mg powder for concentrate and solvent for solution for infusion vials | 10 vial PoM

DETOXIFYING DRUGS › UROPROTECTIVE DRUGS

Mesna

- **INDICATIONS AND DOSE**

Cytotoxic induced urothelial toxicity

- BY MOUTH, OR BY INTRAVENOUS INJECTION
- Adult: Dose to be calculated according to oxazaphosphorine (cyclophosphamide or ifosfamide) treatment (consult product literature)

- **SIDE-EFFECTS**
  - **Common or very common** Appetite decreased · arthralgia · asthenia · chest pain · chills · concentration impaired · conjunctivitis · constipation · cough · dehydration · diarrhoea · dizziness · drowsiness · dry mouth · dyspnoea · dysuria · fever · flatulence · flushing · gastrointestinal discomfort · haemorrhage · headache · hyperhidrosis · influenza like illness · laryngeal discomfort · lymphadenopathy · malaise · myalgia · nasal congestion · nausea · oral irritation · pain · palpitations · respiratory disorders · sensation abnormal · skin reactions · sleep disorders · syncope · vision disorders · vomiting
  - **Frequency not known** Acute kidney injury · angioedema · drug reaction with eosinophilia and systemic symptoms (DRESS) · hypotension · hypoxia · oedema · tachycardia · ulcer · vulvovaginal rash
- **ALLERGY AND CROSS-SENSITIVITY** Contra-indicated if history of hypersensitivity to thiol-containing compounds.
- **PREGNANCY** Not known to be harmful. See also *Pregnancy and reproductive function* in Cytotoxic drugs p. 938.
- **EFFECT ON LABORATORY TESTS** False positive urinary ketones. False positive or false negative urinary erythrocytes.
- **DIRECTIONS FOR ADMINISTRATION** For oral administration of the injection, contents of ampoule are taken in a flavoured drink such as orange juice or cola which may be stored in a refrigerator for up to 24 hours in a sealed container.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

Solution for injection

- Mesna (Non-proprietary)

Mesna 100 mg per 1 ml Mesna 1g/10ml solution for injection ampoules | 15 ampoule PoM £441.15–£447.15
Mesna 400mg/4ml solution for injection ampoules | 5 ampoule PoM £17.00 | 15 ampoule PoM £201.15

Tablet

- Mesna (Non-proprietary)

Mesna 400 mg Mesna 400mg tablets | 10 tablet PoM £134.30
Mesna 600 mg Mesna 600mg tablets | 10 tablet PoM £190.60

VITAMINS AND TRACE ELEMENTS › FOLATES

Folinic acid

12-Apr-2019

- **INDICATIONS AND DOSE**

Prevention of methotrexate-induced adverse effects

- BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION
- Adult: 15 mg every 6 hours for 24 hours, to be started usually 12–24 hours after start of methotrexate infusion, dose may be continued by mouth, consult local treatment protocol for further information

Suspected methotrexate overdosage

- BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION
- Adult: Initial dose equal to or exceeding dose of methotrexate, to be given at a maximum rate of 160 mg/minute, consult poisons information centres for advice on continuing management

Adjunct to fluorouracil in colorectal cancer

- BY SLOW INTRAVENOUS INJECTION
- Adult: (consult product literature)

SODIOFOLIN ®

As an antidote to methotrexate

- BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION
- Adult: (consult product literature)

Adjunct to fluorouracil in colorectal cancer

- BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION
- Adult: (consult product literature)

- **CONTRA-INDICATIONS** Intrathecal injection
- **CAUTIONS** Avoid simultaneous administration of methotrexate · **not** indicated for pernicious anaemia or other megaloblastic anaemias caused by vitamin B_{12} deficiency
- **INTERACTIONS** → Appendix 1: folates
- **SIDE-EFFECTS**

GENERAL SIDE-EFFECTS

- **Uncommon** Fever
- **Rare or very rare** Agitation (with high doses) · depression (with high doses) · epilepsy exacerbated · gastrointestinal disorder (with high doses) · insomnia (with high doses)

SPECIFIC SIDE-EFFECTS

- **Common or very common**
  - With intravenous use Bone marrow failure · dehydration · diarrhoea · mucositis · nausea · oral disorders · skin reactions · vomiting
- **Rare or very rare**
  - With intramuscular use Urticaria